Eli Lilly's Stock Tumbles 15% After Disappointing Obesity Pill Trial Results
Eli Lilly's shares dropped 15% after its obesity pill, orforglipron, failed in Phase III trials, failing to compete with Novo Nordisk's Ozempic, despite positive earnings.
Novo Nordisk News
Novo Nordisk Soars 12% as OMX Copenhagen Index Climbs 6% Amid Eli Lilly's Setback
The OMX Copenhagen 20 index surged over 6%, driven by Novo Nordisk's 12% jump after Eli Lilly's weight-loss drug trial results disappointed, causing Lilly's shares to drop 12.9%. N...
Novo Nordisk's Financial Outlook Sparks 10% Plunge in OMX Copenhagen Index
The OMX Copenhagen Benchmark Index dropped over 10% after Novo Nordisk A/S shares fell by 22% due to a disappointing financial outlook revision, reducing its 2025 sales growth fore...
